These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8738624)

  • 21. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOCCNE).
    Veronesi A; Re GL; Foladore S; Merlo A; Giuliotto N; Talamini R; Monfardini S
    Eur Urol; 1996; 29(4):434-8. PubMed ID: 8791050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
    Fléchon A; Pouessel D; Ferlay C; Perol D; Beuzeboc P; Gravis G; Joly F; Oudard S; Deplanque G; Zanetta S; Fargeot P; Priou F; Droz JP; Culine S
    Ann Oncol; 2011 Nov; 22(11):2476-2481. PubMed ID: 21436186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.
    Buonerba C; Federico P; Bosso D; Puglia L; Policastro T; Izzo M; Perri F; Vittoria Scarpati GD; Ferro M; Cobelli OD; De Placido S; Aieta M; Imbimbo C; Longo N; Di Lorenzo G
    Future Oncol; 2014 Jun; 10(8):1353-60. PubMed ID: 25052746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
    Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
    Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
    Chao D; Harland SJ
    Eur Urol; 1997; 31(1):7-10. PubMed ID: 9032527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.
    Segawa T; Kamoto T; Kinoshita H; Kunishima Y; Yoshimura K; Ito A; Takahashi T; Higashi S; Nakamura E; Nishiyama H; Ito N; Yamamoto S; Habuchi T; Ogawa O
    Int J Clin Oncol; 2005 Oct; 10(5):333-7. PubMed ID: 16247660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.
    Baker WJ; Vukelja SJ; Burrell LM; Lee N; Perry JJ
    Bone Marrow Transplant; 1998 Apr; 21(8):775-8. PubMed ID: 9603400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy with carboplatin, etoposide and epirubicin.
    Nyman CR
    Thorax; 1992 Aug; 47(8):668. PubMed ID: 1329248
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin.
    Tirmazy SH; Barthakur U; El-Modir A; Anwar S; Fernando I
    Anticancer Res; 2014 Jul; 34(7):3793-8. PubMed ID: 24982404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
    Briasoulis E; Tsavaris N; Fountzilas G; Athanasiadis A; Kosmidis P; Bafaloukos D; Skarlos D; Samantas E; Pavlidis N
    Oncology; 1998; 55(5):426-30. PubMed ID: 9732220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.